US5922304A
(en)
|
1989-12-22 |
1999-07-13 |
Imarx Pharmaceutical Corp. |
Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
US5542935A
(en)
|
1989-12-22 |
1996-08-06 |
Imarx Pharmaceutical Corp. |
Therapeutic delivery systems related applications
|
US6551576B1
(en)
|
1989-12-22 |
2003-04-22 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US6088613A
(en)
|
1989-12-22 |
2000-07-11 |
Imarx Pharmaceutical Corp. |
Method of magnetic resonance focused surgical and therapeutic ultrasound
|
US5776429A
(en)
|
1989-12-22 |
1998-07-07 |
Imarx Pharmaceutical Corp. |
Method of preparing gas-filled microspheres using a lyophilized lipids
|
US20020150539A1
(en)
*
|
1989-12-22 |
2002-10-17 |
Unger Evan C. |
Ultrasound imaging and treatment
|
US6605712B1
(en)
*
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
JP3337214B2
(ja)
*
|
1990-12-20 |
2002-10-21 |
アーチ・ディベロップメント・コーポレーション |
電離線による遺伝子発現の調節
|
US5205290A
(en)
|
1991-04-05 |
1993-04-27 |
Unger Evan C |
Low density microspheres and their use as contrast agents for computed tomography
|
US5874062A
(en)
|
1991-04-05 |
1999-02-23 |
Imarx Pharmaceutical Corp. |
Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
|
WO1994017208A1
(en)
*
|
1993-01-21 |
1994-08-04 |
President And Fellows Of Harvard College |
Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound
|
US7083572B2
(en)
*
|
1993-11-30 |
2006-08-01 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Therapeutic delivery systems
|
AUPM322393A0
(en)
*
|
1993-12-24 |
1994-01-27 |
Austin Research Institute, The |
Mucin carbohydrate compounds and their use in immunotherapy
|
US7592317B1
(en)
|
1994-08-11 |
2009-09-22 |
The University Of Chicago |
Constitutive gene expression in conjuction with ionizing radiation
|
US8021667B2
(en)
|
1994-11-16 |
2011-09-20 |
Macfarlane Burnet Institute For Medical Research And Public Health Ltd |
Compositions for immunotherapy and uses thereof
|
US6548643B1
(en)
|
1994-11-16 |
2003-04-15 |
Austin Research Institute |
Antigen carbohydrate compounds and their use in immunotherapy
|
US6743779B1
(en)
|
1994-11-29 |
2004-06-01 |
Imarx Pharmaceutical Corp. |
Methods for delivering compounds into a cell
|
US5962424A
(en)
*
|
1995-02-21 |
1999-10-05 |
Arch Development Corporation |
Methods and compositions for targeting selectins
|
AU4994596A
(en)
*
|
1995-03-01 |
1996-09-18 |
Cornell Research Foundation Inc. |
Interdependent adenoviral vectors and methods of using same
|
US5997898A
(en)
|
1995-06-06 |
1999-12-07 |
Imarx Pharmaceutical Corp. |
Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
|
US6231834B1
(en)
|
1995-06-07 |
2001-05-15 |
Imarx Pharmaceutical Corp. |
Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
|
US6139819A
(en)
|
1995-06-07 |
2000-10-31 |
Imarx Pharmaceutical Corp. |
Targeted contrast agents for diagnostic and therapeutic use
|
US6521211B1
(en)
*
|
1995-06-07 |
2003-02-18 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Methods of imaging and treatment with targeted compositions
|
CA2191903A1
(en)
*
|
1995-12-20 |
1997-06-21 |
Jun Ikeda |
Stress proteins
|
ATE345682T1
(de)
|
1996-05-01 |
2006-12-15 |
Imarx Pharmaceutical Corp |
In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
|
US6414139B1
(en)
|
1996-09-03 |
2002-07-02 |
Imarx Therapeutics, Inc. |
Silicon amphiphilic compounds and the use thereof
|
DE69737915T2
(de)
|
1996-09-11 |
2008-03-13 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Verfahren zur diagnostischen Bilderzeugung der Nierenregion unter Verwendung eines Kontrastmittels und eines Vasodilators
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
IL131776A0
(en)
*
|
1997-03-10 |
2001-03-19 |
Res Dev Foundation |
Photodynamic therapy generated oxidative stress for temporal and selective expression of heterologous genes
|
AU742365B2
(en)
*
|
1997-03-14 |
2002-01-03 |
Selective Genetics, Inc. |
Adenoviral vectors with modified tropism
|
US6143276A
(en)
|
1997-03-21 |
2000-11-07 |
Imarx Pharmaceutical Corp. |
Methods for delivering bioactive agents to regions of elevated temperatures
|
US6537246B1
(en)
|
1997-06-18 |
2003-03-25 |
Imarx Therapeutics, Inc. |
Oxygen delivery agents and uses for the same
|
US6090800A
(en)
|
1997-05-06 |
2000-07-18 |
Imarx Pharmaceutical Corp. |
Lipid soluble steroid prodrugs
|
US20050019266A1
(en)
*
|
1997-05-06 |
2005-01-27 |
Unger Evan C. |
Novel targeted compositions for diagnostic and therapeutic use
|
US6416740B1
(en)
|
1997-05-13 |
2002-07-09 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Acoustically active drug delivery systems
|
US6548047B1
(en)
|
1997-09-15 |
2003-04-15 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Thermal preactivation of gaseous precursor filled compositions
|
DK1027063T3
(da)
|
1997-09-29 |
2009-06-02 |
Macfarlane Burnet Inst For Med |
Mannosereceptorbærende cellelinje og antigensammensætning
|
EP1029052B1
(de)
|
1997-11-06 |
2010-08-04 |
Novartis Vaccines and Diagnostics S.r.l. |
Neisseriale antigene
|
WO1999025385A1
(en)
*
|
1997-11-17 |
1999-05-27 |
Imarx Pharmaceutical Corp. |
A method of increasing nucleic acid synthesis with ultrasound
|
JP2001525173A
(ja)
*
|
1997-12-04 |
2001-12-11 |
ジェンザイム・コーポレーション |
遺伝子発現を誘導するための組成物および方法
|
US6123923A
(en)
|
1997-12-18 |
2000-09-26 |
Imarx Pharmaceutical Corp. |
Optoacoustic contrast agents and methods for their use
|
DE69941567D1
(de)
|
1998-01-14 |
2009-12-03 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
US20010003580A1
(en)
|
1998-01-14 |
2001-06-14 |
Poh K. Hui |
Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
|
ES2294629T3
(es)
|
1998-05-01 |
2008-04-01 |
Novartis Vaccines And Diagnostics, Inc. |
Antigenos de neisseria y composiciones.
|
US6380393B1
(en)
|
1999-03-19 |
2002-04-30 |
San Diego State University Foundation |
Ligands, transition metal complexes and methods of using same
|
ES2397918T3
(es)
|
1999-04-30 |
2013-03-12 |
Novartis Vaccines And Diagnostics S.R.L. |
Antígenos Neisseriales conservados
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
ES2564463T3
(es)
|
1999-10-29 |
2016-03-22 |
Glaxosmithkline Biologicals S.A. |
Péptidos antigénicos de Neisseriales
|
WO2001036640A2
(en)
|
1999-11-18 |
2001-05-25 |
Chiron Corporation |
Human fgf-21 gene and gene expression products
|
PT2289545T
(pt)
|
2000-01-17 |
2016-09-06 |
Glaxosmithkline Biologicals Sa |
Vacina de omv suplementada contra meningococos
|
EP1854476A3
(de)
|
2000-02-09 |
2008-05-07 |
Bas Medical, Inc. |
Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
|
JP2003531583A
(ja)
|
2000-03-08 |
2003-10-28 |
カイロン コーポレイション |
ヒトfgf−23遺伝子および遺伝子発現産物
|
WO2001090339A2
(en)
*
|
2000-05-23 |
2001-11-29 |
Warner-Lambert Company |
Methods and compositions to activate genes in cells
|
EP1950297A2
(de)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
DE60134275D1
(de)
|
2000-06-15 |
2008-07-10 |
Novartis Vaccines & Diagnostic |
Polynukleotide zur bestimmung von kolonkrebs
|
US6579522B1
(en)
|
2000-06-27 |
2003-06-17 |
Genvec, Inc. |
Replication deficient adenoviral TNF vector
|
EP2284182A1
(de)
|
2000-10-27 |
2011-02-16 |
Novartis Vaccines and Diagnostics S.r.l. |
Nukleinsäuren und Proteine von Streptokokkengruppen A und B
|
CA2430379A1
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
AU2002303247B2
(en)
*
|
2001-04-06 |
2005-03-24 |
Dana-Farber Cancer Institute |
Chemotherapeutic induction of Egr-1 promoter activity
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
KR20030022094A
(ko)
|
2001-05-24 |
2003-03-15 |
(주)휴먼디엔에이테크놀로지 |
모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
EP2335723A1
(de)
|
2001-12-12 |
2011-06-22 |
Novartis Vaccines and Diagnostics S.r.l. |
Immunisierung gegen Chlamydia trachomatis
|
CA2472282A1
(en)
|
2002-01-08 |
2003-07-17 |
Chiron Corporation |
Gene products differentially expressed in cancerous breast cells and their methods of use
|
CA2476888A1
(en)
*
|
2002-02-01 |
2003-08-14 |
Vanderbilt University |
Targeted drug delivery methods
|
CA2479730A1
(en)
|
2002-03-21 |
2003-10-02 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
EP1532161B1
(de)
|
2002-06-13 |
2012-02-15 |
Novartis Vaccines and Diagnostics, Inc. |
Vektoren zur expression von hml-2-polypeptiden
|
AU2003288660A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
EP2058408A3
(de)
|
2003-02-14 |
2009-09-09 |
Sagres Discovery, Inc. |
Therapeutische GPCR-Targets für Karzinome
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
EP1687032B1
(de)
*
|
2003-11-14 |
2010-02-24 |
Genvec, Inc. |
Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
|
CN104292321A
(zh)
|
2004-03-29 |
2015-01-21 |
株式会社嘉尔药物 |
新的半乳凝素9 突变体蛋白质及其用途
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
WO2006026348A1
(en)
*
|
2004-08-25 |
2006-03-09 |
The University Of Chicago |
Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
|
US7939490B2
(en)
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
EP1858919B1
(de)
|
2005-02-18 |
2012-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Immungene von uropathogenen escherichia coli
|
EP2062591A1
(de)
|
2005-04-07 |
2009-05-27 |
Novartis Vaccines and Diagnostics, Inc. |
CACNA1E in der Krebsdiagnose-Erkennung und -Behandlung
|
WO2006110585A2
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cancer-related genes (prlr)
|
JP5976986B2
(ja)
*
|
2005-10-01 |
2016-08-24 |
チャールズ スタウト, |
調節可能な融合プロモーター
|
PL2054431T3
(pl)
|
2006-06-09 |
2012-07-31 |
Novartis Ag |
Konformery adhezyn bakteryjnych
|
WO2008020330A2
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
JP2012519482A
(ja)
|
2009-03-06 |
2012-08-30 |
ノバルティス アーゲー |
クラミジア抗原
|
SI2510947T1
(sl)
|
2009-04-14 |
2016-05-31 |
Glaxosmithkline Biologicals S.A. |
Sestavki za imunizacijo proti Staphylococcus aureus
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
CN102770443A
(zh)
|
2009-07-16 |
2012-11-07 |
诺华有限公司 |
脱毒大肠杆菌免疫原
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US20210047425A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
WO2021195218A1
(en)
|
2020-03-24 |
2021-09-30 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
AU2021244555A1
(en)
|
2020-03-24 |
2022-11-24 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|